TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

第3相 完了 NCT02676076

概要

Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose Inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate (FF) plus glycopyrronium bromide \[GB\]) versus CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate (BDP) plus formoterol fumarate \[FF\]), with regard to lung functions parameters and rate of exacerbations as well as safety and health economics outcomes, in adult patients with uncontrolled asthma on medium doses of inhaled corticosteroids in combination with long acting ß2 agonists (LABA).

1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26

Week 0 (pre-treatment, baseline) to Week 26. · Liter

2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment Period

Week 0 (pre-treatment, baseline) to Week 52. · events/year

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
• Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
• A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
• A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
• A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
• Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca

すべての治験